207_Combined course Presentations

First page Table of contents Previous page 547 Next page Last page

Checkpoint blocade

48h

CTLA-4 inhibition Ipilimumab/Tremelimumab

PD-L1 inhibition Pembrolizumab/Nivolumab/ Duravulumab/Avelumab

Ribas NEJM 2012

Made with